C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation.

[1]  B. Storer,et al.  Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  T. Braun,et al.  Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. , 2017, Biology of Blood and Marrow Transplantation.

[3]  J. Magenau,et al.  Advances in understanding the pathogenesis of graft‐versus‐host disease , 2016, British journal of haematology.

[4]  B. Storer,et al.  Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. , 2015, Blood.

[5]  M. Pasquini,et al.  Acute graft-versus-host disease: a bench-to-bedside update. , 2014, Blood.

[6]  H. Sengeløv,et al.  T-Cell Chimerism Is Valuable in Predicting Early Mortality in Steroid-Resistant Acute Graft-versus-Host Disease after Myeloablative Allogeneic Cell Transplantation , 2014, Acta Haematologica.

[7]  I. Christensen,et al.  Pretransplant C‐reactive Protein as A Prognostic Marker in Allogeneic Stem Cell Transplantation , 2014, Scandinavian journal of immunology.

[8]  T. Braun,et al.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. , 2013, The New England journal of medicine.

[9]  E. Snarski,et al.  Inflammatory Markers in Patients after Hematopoietic Stem Cell Transplantation , 2013, Archivum Immunologiae et Therapiae Experimentalis.

[10]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[11]  J. Wingard,et al.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  R. Porcher,et al.  Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. , 2012, Blood.

[13]  E. Shpall,et al.  Steroid-Refractory Acute GVHD: Predictors and Outcomes , 2011, Advances in hematology.

[14]  R. Storb,et al.  Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  R. Storb,et al.  Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. , 2011, Blood.

[16]  T. Feuth,et al.  Intestinal Damage Determines the Inflammatory Response and Early Complications in Patients Receiving Conditioning for a Stem Cell Transplantation , 2010, PloS one.

[17]  J. Bolaños-Meade,et al.  Graft-versus-host disease treatment: predictors of survival. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  M. V. D. van den Brink,et al.  Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. , 2010, Blood.

[19]  S. Choi,et al.  Pathogenesis and management of graft-versus-host disease. , 2010, Immunology and allergy clinics of North America.

[20]  M. Hessner,et al.  Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. , 2009, Blood.

[21]  T. Zima,et al.  Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study , 2009, Critical care.

[22]  Thomas M Braun,et al.  A biomarker panel for acute graft-versus-host disease. , 2009, Blood.

[23]  S. Yamasaki,et al.  Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[25]  J. W. Lee,et al.  Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse , 2006, Bone Marrow Transplantation.

[26]  E. Holler,et al.  Evaluation of C‐reactive protein, interleukin‐6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients , 2006, European journal of haematology.

[27]  R. Schots,et al.  An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation , 2002, Bone Marrow Transplantation.

[28]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[29]  H. Tilg,et al.  Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation. , 1994, Transplantation.

[30]  P. Sehgal,et al.  THE RELATIONSHIP OF SERUM IL‐6 LEVELS TO ACUTE GRAFT‐VERSUS‐HOST DISEASE AND HEPATORENAL DISEASE AFTER HUMAN BONE MARROW TRANSPLANTATION , 1992, Transplantation.

[31]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[32]  A. Gautier,et al.  C-reactive protein , 2005 .

[33]  T. Braun,et al.  A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. , 2015, The Lancet. Haematology.

[34]  M. Remberger.  Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. , 2005, Haematologica.